Commande rapide

Text Size:AAA

CD166/ALCAM  Protéine

All CD166 Reagents

Hôte d’expression: Human Cells  
  • Slide 1
10045-H08H-100
10045-H08H-200
100 µg 
200 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
50005-M03H-50
50005-M03H-100
50 µg 
100 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
50005-M08H-50
50005-M08H-100
50 µg 
100 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
80221-R08H-50
80221-R08H-100
50 µg 
100 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
80221-R02H-50
80221-R02H-100
50 µg 
100 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
90227-C02H-100
90227-C02H-50
100 µg 
50 µg 
Add to Cart
Hôte d’expression: Human Cells  
  • Slide 1
90227-C08H-100
90227-C08H-200
100 µg 
200 µg 
Add to Cart

Browse CD166/ALCAM Products by

CD166/ALCAM Voies apparentées

CD166/ALCAM Produits apparentés

CD166/ALCAM Produits apparentés

Featured Reagent Products

CD166/ALCAM Récapitulatif et informations sur les protéines

CD166/ALCAM Fond

Résumé du gène: This ALCAM gene encodes activated leukocyte cell adhesion molecule (ALCAM), also known as CD166 (cluster of differentiation 166), which is a member of a subfamily of immunoglobulin receptors with five immunoglobulin-like domains (VVC2C2C2) in the extracellular domain. This protein binds to T-cell differentiation antigene CD6, and is implicated in the processes of cell adhesion and migration. Multiple alternatively spliced transcript variants encoding different isoforms have been found.
General information above from NCBI
Domaine: The CD6 binding site is located in the N-terminal Ig-like domain.
Localisation subcellulaire: Membrane; Single-pass type I membrane protein.
Spécificité tissulaire: Spleen, placenta, liver, and weakly in liver. Expressed by activated T-cells, B-cells, monocytes and thymic epithelial cells. Expressed by neurons in the brain. Restricted expression in tumor cell lines. Preferentially expressed in highly metastasizing melanoma cell lines.
Similarité de séquence: Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 2 Ig-like V-type (immunoglobulin-like) domains.C
General information above from UniProt

Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.

CD166/ALCAM Autre dénomination

CD166/ALCAM Études apparentées

  • Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
  • Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
  • Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
  • Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.
  • Veuillez noter : Tous les produits sont « DESTINÉS À LA RECHERCHE UNIQUEMENT ET NE SONT PAS PRÉVUS POUR ÊTRE UTILISÉS À DES FINS DE DIAGNOSTIC OU THÉRAPEUTIQUES »